These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. [The influence of MIF (melanocyte-stimulating hormone-release inhibiting factor) on psychomotor function and mood in parkinsonian patients. Preliminary report (author's transl)]. Schneider E; Fischer PA; Jacobi P; Reh W Arzneimittelforschung; 1978; 28(8):1296-7. PubMed ID: 37848 [TBL] [Abstract][Full Text] [Related]
9. Treatment of endogenous depressions with thyrotropin-releasing hormone (TRH) under oral administration. Schmidt J Acta Psychiatr Scand; 1977 Feb; 55(2):142-6. PubMed ID: 402795 [TBL] [Abstract][Full Text] [Related]
10. Comparison of thyrotropin-releasing hormone with melanocyte-stimulating-hormone-release-inhibiting factor as pentobarbital antagonists in monkeys. Crowley TJ; Hydinger M Psychopharmacology (Berl); 1977 Jul; 53(2):205-6. PubMed ID: 19803 [TBL] [Abstract][Full Text] [Related]
11. MIF, TRH, and simian social and motor behavior. Crowley TJ; Hydinger M Pharmacol Biochem Behav; 1976; 5(Suppl 1):79-87. PubMed ID: 13417 [TBL] [Abstract][Full Text] [Related]
12. TRH in depressive illness. Pecknold JC; Ban TA Int Pharmacopsychiatry; 1977; 12(3):166-73. PubMed ID: 410749 [TBL] [Abstract][Full Text] [Related]
13. The effect of LHRH and TRH on human interferon-gamma production in vivo and in vitro. Grasso G; Massai L; De Leo V; Muscettola M Life Sci; 1998; 62(22):2005-14. PubMed ID: 9627099 [TBL] [Abstract][Full Text] [Related]
14. Neurologically active peptides. Barbeau A; Gonce M; Kastin AJ Pharmacol Biochem Behav; 1976; 5(Suppl 1):159-63. PubMed ID: 13415 [TBL] [Abstract][Full Text] [Related]
15. Behavioral and hormonal effects of prolonged high doses of LHRH in male impotency. Ehrensing RH; Kastin AJ; Schally AV Peptides; 1981; 2 Suppl 1():115-21. PubMed ID: 7022397 [TBL] [Abstract][Full Text] [Related]
16. Neurotropic and pituitary effects of melanostatin (MIF), thyroliberin (TRH) and structurally related peptides. Björkman S Acta Pharm Suec; 1980; 17(6):352. PubMed ID: 6111892 [No Abstract] [Full Text] [Related]
17. CNS and pituitary effects of hypothalamic peptides and MSH. Kastin AJ; Miller LH; Sandman CA; Schally AV; Plotnikoff NP Essays Neurochem Neuropharmacol; 1977; 1():139-76. PubMed ID: 30623 [TBL] [Abstract][Full Text] [Related]
18. Intensification of central catecholaminergin and serotonergic processes by the hypothalamic factors MIF and TRF and by angiotensin II. Huidobro-Toro JP; Scotti de Carolis A; Longo VG Pharmacol Biochem Behav; 1975; 3(2):235-42. PubMed ID: 238221 [TBL] [Abstract][Full Text] [Related]
19. Peripheral administration of hypothalamic peptides results in CNS changes. Kastin AJ; Coy DH; Schally AV; Miller LH Pharmacol Res Commun; 1978 Apr; 10(4):293-312. PubMed ID: 28532 [No Abstract] [Full Text] [Related]